mitoxantrone + fludarabine + prednisone

Mitoxantrone + fludarabine + prednisone is a chemotherapeutic combination regimen, sometimes referred to as the FMP regimen, primarily investigated and used for the treatment of recurrent low-grade non-Hodgkin's lymphoma (LG-NHL). - **Fludarabine** is a purine analog antimetabolite that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase, inducing apoptosis especially in lymphoid cells. - **Mitoxantrone** is an anthracenedione antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, causing DNA strand breaks and apoptosis. - **Prednisone** is a synthetic glucocorticoid corticosteroid that induces apoptosis in sensitive lymphoid cells and modulates immune response. The combination is used to exploit additive or synergistic cytotoxic effects, aiming for increased efficacy and moderate toxicity in relapsed or refractory indolent lymphoproliferative disorders[1][3][6]. Published clinical studies confirm significant remission rates (CR and PR) in recurrent LG-NHL populations, with predominant toxicities including neutropenia and infections[3][1].

Other names

FMP regimen